Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2020

01-12-2020 | Breast Cancer | Research

Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy

Authors: Sheng Chang, Gang Liu, Lewei Zhao, Joshua T. Dilworth, Weili Zheng, Saada Jawad, Di Yan, Peter Chen, Craig Stevens, Peyman Kabolizadeh, Xiaoqiang Li, Xuanfeng Ding

Published in: Radiation Oncology | Issue 1/2020

Login to get access

Abstract

Background

This study investigated the feasibility and potential clinical benefit of utilizing a new proton treatment technique: Spot-scanning proton arc (SPArc) therapy for left-sided whole breast radiotherapy (WBRT) to further reduce radiation dose to healthy tissue and mitigate the probability of normal tissue complications compared to conventional intensity modulated proton therapy (IMPT).

Methods

Eight patients diagnosed with left-sided breast cancer and treated with breast-preserving surgery followed by whole breast irradiation without regional nodal irradiation were included in this retrospective planning. Two proton treatment plans were generated for each patient: vertical intensity-modulated proton therapy used for clinical treatment (vIMPT, gantry angle 10°–30°) and SPArc for comparison purpose. Both SPArc and vIMPT plans were optimized using the robust optimization of ± 3.5% range and 5 mm setup uncertainties. Root-mean-square deviation dose (RMSD) volume histograms were used for plan robustness evaluation. All dosimetric results were evaluated based on dose-volume histograms (DVH), and the interplay effect was evaluated based on the accumulation of single-fraction 4D dynamic dose on CT50. The treatment beam delivery time was simulated based on a gantry rotation with energy-layer-switching-time (ELST) from 0.2 to 5 s.

Results

The average D1 to the heart and LAD were reduced to 53.63 cGy and 82.25 cGy compared with vIMPT 110.38 cGy (p = 0.001) and 170.38 cGy (p = 0.001), respectively. The average V5Gy and V20Gy of ipsilateral lung was reduced to 16.77% and 3.07% compared to vIMPT 25.56% (p = 0.001) and 4.68% (p = 0.003). Skin3mm mean and maximum dose were reduced to 3999.38 cGy and 4395.63 cGy compared to vIMPT 4104.25 cGy (p = 0.039) and 4411.63 cGy (p = 0.043), respectively. A significant relative risk reduction (RNTCP = NTCPSPArc/NTCPvIMPT) for organs at risk (OARs) was obtained with SPArc ranging from 0.61 to 0.86 depending on the clinical endpoint. The RMSD volume histogram (RVH) analysis shows SPArc provided better plan robustness in OARs sparing, including the heart, LAD, ipsilateral lung, and skin. The average estimated treatment beam delivery times were comparable to vIMPT plans when the ELST is about 0.5 s.

Conclusion

SPArc technique can further reduce dose delivered to OARs and the probability of normal tissue complications in patients treated for left-sided WBRT.
Appendix
Available only for authorised users
Literature
1.
International Agency for Research on Cancer. Latest world cancer statistics Global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. Geneva: World Health Organization; 2013. p. 12.
2.
Giordano SH, Kuo YK, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvantradiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–24.PubMedCrossRef
3.
Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100–6.PubMedCrossRef
4.
Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–75.PubMedCrossRef
5.
Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63(1):214–23.PubMedCrossRef
6.
Lind PA, Pagnanelli R, Marks LB, et al. Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys. 2003;55(4):914–20.PubMedCrossRef
7.
Huang JH, Wu XX, Lin X, Shi JT, Ma YJ, Duan S, et al. Evaluation of fixed-jaw IMRT and tangential partial-VMAT radiotherapy plans for synchronous bilateral breast cancer irradiation based on a dosimetric study. J Appl Clin Med Phys. 2019;20(9):31–41.PubMedPubMedCentralCrossRef
8.
Tuomas V, Janne H, Kimmo M, Kristiina K, Topani L, Jan S. Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy. Radiat Oncol. 2015;10:79.CrossRef
9.
Yu PC, Wu CJ, Nien HH, Lui LT, Shaw S, Tsai YL. Tangent-based volumetric modulated arc therapy for advanced left breast cancer. Radiat Oncol. 2018;13:236.PubMedPubMedCentralCrossRef
10.
Ares C, Khan S, MacArtain AM, Heuberger J, Goitein G, Gruber G, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys. 2010;76:685–97.PubMedCrossRef
11.
Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–65.CrossRefPubMed
12.
Nilsson G, Holmberg L, Garmo H, Duvernoy O, Sjögren I, Lagerqvist B, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2012;30:380–6.PubMedCrossRef
13.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.CrossRefPubMed
14.
Shah C, Badiyan S, Berry S, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiother Oncol. 2014;112:9–16.PubMedCrossRef
15.
Mast ME, Vredeveld EJ, Credoe HM, van Egmond J, Heijenbrok MW, Hug EB, et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Br Cancer Res Treat. 2014;148:33–9.CrossRef
16.
Tommasino F, Durante M, D’Avino V, Liuzzi R, Conson M, Farace P, et al. Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery. Acta Oncol. 2017;56(5):730–6.PubMedCrossRef
17.
Lomax AJ, et al. The clinical potential of intensity modulated proton therapy. Z Med Phys. 2004;14(3):147–52.PubMedCrossRef
18.
Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol. 2008a;53(4):1027–42.PubMedCrossRef
19.
Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and interfiled motions. Phys Med Biol. 2008b;53(4):1043–56.PubMedCrossRef
20.
Dowdell S, et al. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. Phys Med Biol. 2013;58(12):4137–56.PubMedPubMedCentralCrossRef
21.
Knopf AC, Hong TS, Lomax A. Scanned proton radiotherapy for mobile targets-the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics. Phys Med Biol. 2011;56(22):7257–71.PubMedCrossRef
22.
Unkelbach J, et al. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. Med Phys. 2009;36(1):149–63.PubMedCrossRef
23.
Liao L, Lim GJ, Li Y, et al. Robust optimization for intensity modulated proton therapy plans with multi-isocenter large fields. Int J Part Ther. 2016;3(2):305–11.PubMedPubMedCentralCrossRef
24.
Ding X, et al. Spot-scanning proton arc (SPArc) therapy: the first robust and delivery-efficient spot-scanning proton arc therapy. Int J Radiat Oncol Biol Phys. 2016;96(5):1107–16.PubMedCrossRef
25.
Ding X, Li X, Qin A, Zhou J, Yan D, Stevens C, et al. Have we reached proton beam therapy dosimetric limitations? A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018;57(3):435–7.PubMedCrossRef
26.
Liu G, Li X, Qin A, Zheng W, Yan D, Zhang S, et al. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study. Radiat Oncol. 2020;15(1):21.PubMedPubMedCentralCrossRef
27.
Li X, Kabolizadeh P, Yan D, et al. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy. Radiat Oncol. 2018;13:35.PubMedPubMedCentralCrossRef
28.
Ding X, Zhou J, Li X, et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019;58:483–90.PubMedCrossRef
29.
RTOG. Breast cancer atlas for radiation therapy planning: consensus definitions (2017).
30.
Shaitelman SF, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1(7):931–41.PubMedPubMedCentralCrossRef
31.
Whelan TJ, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.PubMedCrossRef
32.
Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol. 2012;83:1169–78.CrossRef
33.
Liu W, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. Med Phys. 2013;40(5):051711.PubMedPubMedCentralCrossRef
34.
Kardar L, et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014;4(6):e259–68.PubMedPubMedCentralCrossRef
35.
Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:249–62.PubMedCrossRef
36.
Pastore F, Conson M, D’avino V, et al. Dose-surface analysis for prediction of severe acute radio-induced skin toxicity in breast cancer patients. Acta Oncol. 2016;55:466–73.PubMedCrossRef
37.
Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, Henning GT, Hayman JA, Martel MK, Ten Haken RK. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724–35.PubMedCrossRef
38.
Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13–9.PubMedCrossRef
39.
Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after radiotherapy of breast cancerdapplication of the relative seriality model. Br J Radiol. 1996;69:839–46.PubMedCrossRef
40.
Koschik A, Bula C, Duppich J, et al. Gantry 3: further development of the psi proscan proton therapy facility. In: Proceedings of IPAC 2015, Richmond, VA, USA TUPWI016.
41.
Michalski A, Atyeo J, Cox J, Rinks M. Inter- and intra-fraction motion during radiation therapy to the whole breast in the supine position: a systematic review. J Med Imaging Radiat Oncol. 2012;56(5):499–509.PubMedCrossRef
42.
Miller D, Klein E, Zoberi I, Taylor M, Powell S. Inter-fraction and intra-fraction breast motion localized using AlignRT for early breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:S189–90.CrossRef
43.
Lee J, Liu SH, Lin JB, et al. Image-guided study of inter-fraction and intra-fraction set-up variability and margins in reverse semi-decubitus breast radiotherapy. Radiat Oncol. 2018;13(1):254.PubMedPubMedCentralCrossRef
44.
Taylor AM, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast cancer radiotherapy: a systematic review of heart doses published during 2003–2013. Int J Radiat Oncol Biol Phys. 2015;93:845–53.PubMedCrossRef
45.
Rehammar JC, Jensen MB, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005. Radiother Oncol. 2017;123:299–305.PubMedPubMedCentralCrossRef
46.
47.
Jacob S, Camilleri J, Derreumaux S, et al. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019;14:29.PubMedPubMedCentralCrossRef
48.
Becker-Schiebe M, Stockhammer M, Hoffmann W, et al. Does mean heart dose sufficiently reflect coronary artery exposure in left-sided breast cancer radiotherapy? Strahlenther Onkol. 2016;192:624–31.PubMedCrossRef
49.
Bekelman JE, Lu H, Pugh S, et al. Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. BMJ Open. 2019;9(10):e025556.PubMedPubMedCentralCrossRef
50.
van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35:1171–8.PubMedPubMedCentralCrossRef
51.
Jimenez RB, Goma C, Nyamwanda J, Kooy HM, Halabi T, Napolitano BN, et al. Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study. Radiother Oncol. 2013;107:213–7.PubMedCrossRef
52.
Xu N, Ho MW, Li Z, Morris CG, Mendenhall NP. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? Am J Clin Oncol. 2014;37:568–74.PubMedCrossRef
53.
MacDonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86:484–90.PubMedCrossRef
54.
Grassberger C, Dowdell S, Lomax A, et al. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2013;86(2):380–6.PubMedPubMedCentralCrossRef
55.
Kang M, Huang S, Solberg TD, et al. A study of the beam-specific interplay effect in proton pencil beam scanning delivery in lung cancer. Acta Oncol. 2017;56(4):531–40.PubMedCrossRef
56.
Poulsen PR, Eley J, Langner U, et al. Efficient interplay effect mitigation for proton pencil beam scanning by spot-adapted layered repainting evenly spread out over the full breathing cycle. Int J Radiat Oncol Biol Phys. 2018;100(1):226–34.PubMedCrossRef
57.
Engwall E, Fredriksson A, Glimelius L. 4D robust optimization including uncertainties in time structures can reduce the interplay effect in proton pencil beam scanning radiation therapy. Med Phys. 2018;45(9):4020–9.CrossRef
58.
Alshaikhi J, Doolan PJ, D’Souza D, et al. Impact of varying planning parameters on proton pencil beam scanning dose distributions in four commercial treatment planning systems. Med Phys. 2019;46:1150–62.PubMedCrossRef
Metadata
Title
Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy
Authors
Sheng Chang
Gang Liu
Lewei Zhao
Joshua T. Dilworth
Weili Zheng
Saada Jawad
Di Yan
Peter Chen
Craig Stevens
Peyman Kabolizadeh
Xiaoqiang Li
Xuanfeng Ding
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2020
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-020-01676-3

Other articles of this Issue 1/2020

Radiation Oncology 1/2020 Go to the issue

Research

MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria

Methodology

Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer

Research

Dosimetric parameters predict radiation-induced choanal stenosis in patients with nasopharyngeal carcinoma

Research

A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Research

Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study

Research

Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition